Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) Sees Significant Increase in Short Interest

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) was the recipient of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 731,000 shares, an increase of 15.7% from the January 15th total of 631,800 shares. Based on an average daily volume of 1,930,000 shares, the short-interest ratio is presently 0.4 days.

Petros Pharmaceuticals Trading Up 18.4 %

Shares of NASDAQ:PTPI traded up $0.05 on Friday, hitting $0.29. The company had a trading volume of 107,200,541 shares, compared to its average volume of 383,633. The firm’s 50-day simple moving average is $0.32 and its two-hundred day simple moving average is $0.33. Petros Pharmaceuticals has a 1 year low of $0.22 and a 1 year high of $1.76. The company has a quick ratio of 0.74, a current ratio of 0.85 and a debt-to-equity ratio of 1.58. The firm has a market capitalization of $2.94 million, a price-to-earnings ratio of -0.06 and a beta of 1.84.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).